Figure 2.

(A) Vaccination scheme and animal groups. (B) Levels of anti-SIV p27 IgA (top 3 panels), anti-gp70-V1V2 IgA (middle panels) and anti-SIV p27 IgG in saliva (left column), rectal (middle column), and vaginal secretions (right column) were measured by BAMA and normalized relative to concentrations of total IgA or IgG, determined by ELISA. The specific activity (ng IgA or IgG antibody/µg total IgA or IgG, respectively) for individual animals at four time points during vaccination is reported. The dashed line denotes the cut-off for significance and was calculated as the mean specific activity + 3 SD for pre-immunization samples. The specific activity had to exceed the dotted line and be 3 times higher than the animal’s pre-immune sample to be considered significant. A few samples with insufficient total IgA or IgG were not tested for SHIV-specific antibodies.